234
Views
6
CrossRef citations to date
0
Altmetric
Cell Cycle News & Views

Gender, mutant p53 and PML: A growing “affaire” in tumor suppression and oncogenesis

, &
Pages 1824-1825 | Received 16 May 2013, Accepted 20 May 2013, Published online: 05 Jun 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Robert D. Kendig, Fumitake Kai, Elizabeth A. Fry & Kazushi Inoue. (2017) Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α. Cancer Investigation 35:5, pages 301-312.
Read now

Articles from other publishers (5)

Li Ren, Yuhan Qi, Jichun Zhao, Chengxin Weng, Jiarong Wang, Ding Yuan & Tiehao Wang. (2023) Gender Differences in Prognosis After Primary Resection for Retroperitoneal Liposarcoma. The American Surgeon™.
Crossref
Rong Chen, Meng Zhao, Yanli An, Dongfang Liu, Qiusha Tang & Gaojun Teng. (2022) A Prognostic Gene Signature for Hepatocellular Carcinoma. Frontiers in Oncology 12.
Crossref
Chao He, Lun Li, Xuan Guan, Li Xiong & Xiongying Miao. (2017) Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy. Chemotherapy 62:1, pages 43-53.
Crossref
Sue Haupt, Dinesh Raghu & Ygal Haupt. (2016) Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways. Frontiers in Oncology 6.
Crossref
KATE HUANG, LIN CHEN, JILIANG ZHANG, ZHI WU, LINHUA LAN, LU WANG, BIN LU & YONGZHANG LIU. (2014) Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma. Oncology Letters 8:4, pages 1441-1446.
Crossref